Registration Now Open for Ingram Micro’s Global ONE Experience – Join Us November 4-5 Online for an Unforgettable Event
7.10.2020 18:30:00 EEST | Business Wire | Press release
For the first time in its history, Ingram Micro Inc. is taking its ONE event to a fully global audience in a completely online interactive experience. Bringing together APAC ONE, EMEA ONE, LATAM ONE and North America ONE enable Ingram Micro to support multiple time zones and languages, while hosting 12 keynotes, 150 sessions and speakers and attendees from more than 60 countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201007005717/en/
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers." Paul Bay, EVP and President, Global Technology Solutions, Ingram Micro Inc. (Graphic: Business Wire)
As part of the experience, localized content and sessions will be provided for each region. Targeted sessions will also be held pre- and post-experience for special guests attending by countries and communities including Ingram Micro’s SMB Alliance and Trust X Alliance. Ingram Micro channel partners and providers are encouraged to register now at https://imaginenext.ingrammicro.com/one.
Ingram Micro’s executive leadership team will kick off this year’s online experience starting with opening remarks from CEO Alain Monié and EVP and President Paul Bay. Additional event highlights include:
- Fireside chats with Cisco CEO Chuck Robbins and IBM President Jim Whitehurst
- Futurist keynote featuring 311 Institute Founder and CEO Matthew Griffin
- Diversity and Inclusion Keynote from Former NASA Space Science Education Lead Hakeem Oluseyi
- Technology and trends keynote from IDC Group Vice President Michelle Bailey
- Executive addresses from global business leaders including Ingram Micro’s SVP of Marketing Jennifer Anaya, EVP Global Cloud Nimesh Davé, and VP of Global Partner Engagement and IoT Sabine Howest
- Special guests including a GRAMMY award winning musician and bands from around the globe
- An inspired address from one of the best-selling authors, and optimistic motivational speakers on the planet
A complete list of speakers and sessions, including the identities of the above artists and motivational speaker, is noted here. Additionally, several key Ingram Micro announcements and strategic initiatives are expected to launch leading up to and throughout the event, including community announcements from SMB Alliance and Trust X Alliance. Live networking, virtual happy hours and AI-powered business matchups are also on tap for attendees.
“We’ve set high expectations, and are excited to have our partners and providers take what they hear, see and experience at ONE and imagine what’s next for their business, their partner ecosystem and their customers,” said Bay. “Together we are working smarter, harder and with a greater purpose. Ingram Micro and the ecosystem of partner excellence we support has never been more relevant to the vitality and success of today’s business landscape locally, regionally and globally…and we’re ready to do even more.”
Channel press and analysts are welcome to register and attend designated sessions of the Nov. 4-5 Ingram Micro ONE Experience.
For more information visit https://imaginenext.ingrammicro.com/one.
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005717/en/
Contact information
Marie Rourke
WhiteFox Marketing
714.292.2199
marie@whitefoxpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 11:13:00 EET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse ™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 10:30:00 EET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane ® Contour™ for the Correction of Temple Hollowing23.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollowing in patients over the age of 21.1,2 This builds on its previous approvals for cheek augmentation and midface contour deficiencies, helping injectors address volume loss across key structural areas.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260322108467/en/ With the broadest Injectable Aesthetics portfolio in the industry, this follows the recent U.S. approval of Restylane Lyft for augmentation of the chin region, adding to its indications to treat the midface, facial folds and wrinkles, back of hands, and the chin.4,5 Together, these approvals demonstrate Galderma’s ongoing commitment to evolving the versatile Restylane portfolio to deliver personalized, natural-looking outcomes that meet diverse patient needs.1,4,6,7 The volume of the temples can dimi
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 06:00:00 EET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom